



Post Authorisation Assessments

Milbemycin / Praziquantel Tablets 12.5 mg/125 mg Flavoured Tablets for Dogs (Milbemycin / Praziquantel) Vm 08749/5159

28 October 2025	Change in legal entity of Marketing Authorisation Holder from EU Generics Limited, 37 Geraldine Road, London, SW18 2NR, United Kingdom to Chanelle Pharmaceuticals Manufacturing Ltd, Loughrea, Co Galway, H62 FH90, Ireland.
18 September 2025	One-off alignment of the product information with version 3 of the QRD template.
18 February 2025	Change in immediate packaging of the finished product: - Other changes. Change in test procedure for the finished product. Minor change in the manufacturing process. Change in the holding time of bulk product. Change in the description of the finished product due to the change in flavouring. Changes in the composition (excipients) of the finished product. Extension of the shelf life of the finished product.
22 December 2024	Submission of an updated CEP for the manufacture of an active substance.
22 December 2024	Submission of an updated CEP for the manufacture of an active substance.
14 July 2022	Updated certificate of suitability from an already approved manufacturer
26 May 2022	Submission of a new Ph. Eur. certificate of suitability for an active substance from a new manufacturer.